FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028070610> ?p ?o ?g. }

• W2028070610 endingPage "180" @default.
• W2028070610 startingPage "170" @default.
• W2028070610 abstract "Following publication of five pivotal randomized trials of concurrent chemo-irradiation for patients with locally advanced cervical cancer (ie, International Federation of Gynecology and Oncology (FIGO] stages IB2–IVA) in 1999 and 2000, the National Cancer Institute issued a Clinical Alert advising that concurrent chemotherapy (typically, single-agent cisplatin) be incorporated into the treatment program of women scheduled to receive definitive pelvic radiotherapy. Although the adoption of this new standard has improved overall survival and decreased the recurrence rate by 50%, for those patients who do relapse, the prognosis is very poor and, ultimately, therapy in this setting is palliative in nature. The Gynecologic Oncology Group (GOG) has now completed eight randomized trials for metastatic and recurrent cervical cancer, all of which have studied cisplatin-based regimens. The eighth trial (protocol 204) compared four cisplatin-based doublets containing paclitaxel, topotecan, vinorelbine, or gemcitabine. Because the vast majority of patients are now expected to receive cisplatin “up front” as part of primary therapy with pelvic radiation, there are concerns for the development of drug-resistant clones in recurrences both inside and outside of the radiation field. The GOG has recently reported the results from a phase II trial evaluating the anti-vascular agent, bevacizumab, in women who were eligible for second-line or third-line therapy for metastatic and/or recurrent disease (protocol 227C). It becomes imperative that we continue to evaluate novel regimens for this disease." @default.
• W2028070610 created "2016-06-24" @default.
• W2028070610 creator A5014611244 @default.
• W2028070610 creator A5055050872 @default.
• W2028070610 date "2009-04-01" @default.
• W2028070610 modified "2023-09-25" @default.
• W2028070610 title "Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group" @default.
• W2028070610 cites W1808173951 @default.
• W2028070610 cites W1840778568 @default.
• W2028070610 cites W1932754573 @default.
• W2028070610 cites W1969328947 @default.
• W2028070610 cites W1972885270 @default.
• W2028070610 cites W1974546699 @default.
• W2028070610 cites W1986847770 @default.
• W2028070610 cites W1987958334 @default.
• W2028070610 cites W2003187434 @default.
• W2028070610 cites W2006675422 @default.
• W2028070610 cites W2019087543 @default.
• W2028070610 cites W2040271544 @default.
• W2028070610 cites W2040281642 @default.
• W2028070610 cites W2043103956 @default.
• W2028070610 cites W2045019491 @default.
• W2028070610 cites W2046507292 @default.
• W2028070610 cites W2049454219 @default.
• W2028070610 cites W2049997077 @default.
• W2028070610 cites W2064737157 @default.
• W2028070610 cites W2072461945 @default.
• W2028070610 cites W2072871546 @default.
• W2028070610 cites W2077469663 @default.
• W2028070610 cites W2079730922 @default.
• W2028070610 cites W2090031841 @default.
• W2028070610 cites W2100785570 @default.
• W2028070610 cites W2102616986 @default.
• W2028070610 cites W2105651363 @default.
• W2028070610 cites W2107769088 @default.
• W2028070610 cites W2126275851 @default.
• W2028070610 cites W2126768246 @default.
• W2028070610 cites W2131538171 @default.
• W2028070610 cites W2142680679 @default.
• W2028070610 cites W2145835533 @default.
• W2028070610 cites W2157769714 @default.
• W2028070610 cites W2167974749 @default.
• W2028070610 cites W2171725862 @default.
• W2028070610 cites W2341443030 @default.
• W2028070610 doi "https://doi.org/10.1053/j.seminoncol.2008.12.008" @default.
• W2028070610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19332251" @default.
• W2028070610 hasPublicationYear "2009" @default.
• W2028070610 type Work @default.
• W2028070610 sameAs 2028070610 @default.
• W2028070610 citedByCount "51" @default.
• W2028070610 countsByYear W20280706102012 @default.
• W2028070610 countsByYear W20280706102013 @default.
• W2028070610 countsByYear W20280706102014 @default.
• W2028070610 countsByYear W20280706102015 @default.
• W2028070610 countsByYear W20280706102016 @default.
• W2028070610 countsByYear W20280706102017 @default.
• W2028070610 countsByYear W20280706102018 @default.
• W2028070610 countsByYear W20280706102019 @default.
• W2028070610 countsByYear W20280706102020 @default.
• W2028070610 countsByYear W20280706102021 @default.
• W2028070610 countsByYear W20280706102022 @default.
• W2028070610 countsByYear W20280706102023 @default.
• W2028070610 crossrefType "journal-article" @default.
• W2028070610 hasAuthorship W2028070610A5014611244 @default.
• W2028070610 hasAuthorship W2028070610A5055050872 @default.
• W2028070610 hasConcept C121608353 @default.
• W2028070610 hasConcept C126322002 @default.
• W2028070610 hasConcept C141071460 @default.
• W2028070610 hasConcept C143998085 @default.
• W2028070610 hasConcept C2776694085 @default.
• W2028070610 hasConcept C2777802072 @default.
• W2028070610 hasConcept C2778220009 @default.
• W2028070610 hasConcept C2778239845 @default.
• W2028070610 hasConcept C2780258809 @default.
• W2028070610 hasConcept C2780350996 @default.
• W2028070610 hasConcept C2780435969 @default.
• W2028070610 hasConcept C2781209748 @default.
• W2028070610 hasConcept C509974204 @default.
• W2028070610 hasConcept C535046627 @default.
• W2028070610 hasConcept C71924100 @default.
• W2028070610 hasConceptScore W2028070610C121608353 @default.
• W2028070610 hasConceptScore W2028070610C126322002 @default.
• W2028070610 hasConceptScore W2028070610C141071460 @default.
• W2028070610 hasConceptScore W2028070610C143998085 @default.
• W2028070610 hasConceptScore W2028070610C2776694085 @default.
• W2028070610 hasConceptScore W2028070610C2777802072 @default.
• W2028070610 hasConceptScore W2028070610C2778220009 @default.
• W2028070610 hasConceptScore W2028070610C2778239845 @default.
• W2028070610 hasConceptScore W2028070610C2780258809 @default.
• W2028070610 hasConceptScore W2028070610C2780350996 @default.
• W2028070610 hasConceptScore W2028070610C2780435969 @default.
• W2028070610 hasConceptScore W2028070610C2781209748 @default.
• W2028070610 hasConceptScore W2028070610C509974204 @default.
• W2028070610 hasConceptScore W2028070610C535046627 @default.
• W2028070610 hasConceptScore W2028070610C71924100 @default.
• W2028070610 hasIssue "2" @default.
• W2028070610 hasLocation W20280706101 @default.
• W2028070610 hasLocation W20280706102 @default.

• next